Description
Poster presentation of the following scientific abstract:Feasibility of dose escalation for non-small-cell lung cancer using proton therapy
Background
With current chemoradiotherapy, local control for non-small-cell lung cancer is between 60 and 85%. Dose escalation to improve locoregional control has been attempted previously, but resulted in improved mortality. Radiotherapy in these earlier trials involved IMRT and 3D-CRT. Mortality was associated with heart dose and esophageal toxicity. We hypothesized that dose escalation may be feasible without a significant increase in dose to heart and esophagus by using proton therapy. The aim of this planning study was to test this hypothesis by making dose escalation proton therapy plans.
Methods
Proton therapy treatment plans were created prescribing 73 Gy to the IGTVp ≥1 cm outside the PRV of the mediastinal envelope, and 64 Gy to the GTV inside the PRV of the envelope. The maximum V70Gy of the mediastinal envelope was 2cm^3 in the voxelwise maximum robust evaluation. Organ at risk doses in the nominal plans were compared to the 60 Gy clinical proton therapy plans.
Results
In the first three treatment plans made so far, dose escalation was feasibly with doses to lung outside GTV, heart and esophagus similar to the 60 Gy plans. More plans will be added and evaluated in the coming months.
Conclusion
Dose escalation to the IGTVp in non-small-cell lung cancer without compromising dose to heart and esophagus is feasible when using proton therapy, especially for patients with an IGTVp lying mostly outside the mediastinal envelope. The clinical translation of these findings requires a subsequent randomized controlled trial.
| Period | 29-Jun-2022 → 1-Jul-2022 |
|---|---|
| Event title | PTCOG 2022 |
| Event type | Conference |
| Location | Miami, United StatesShow on map |
| Degree of Recognition | International |
Keywords
- Radiotherapy
- Non-small cell lung cancer
- Dose escalation
- Treatment Planning
- Organ at risk